Amy E. Lovejoy

Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency

Amy E. Lovejoy, Tom C. Reynolds, Jennifer Visich et al. · Blood · 2006 · 117 citations · Full text

Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography

Guy Young, Karyn Yonekawa, Peggy Nakagawa et al. · Blood Coagulation & Fibrinolysis · 2007 · 105 citations

Anticoagulant Effects, Factor Vii, Reversal Ability +18

Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation

Guy Young, Karyn Yonekawa, Peggy Nakagawa et al. · Blood Coagulation & Fibrinolysis · 2007 · 27 citations

Clot Formation, Pharmacotherapy, Clot Elasticity +19

[9] DNA polymerases from hyperthermophiles

Holly H. Hogrefe, Janice Cline, Amy E. Lovejoy et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 2001 · 25 citations

Nucleic Acid Chemistry, Natural Sciences, Oligonucleotide +2

Acute Prognostic Factors for Post-Thrombotic Syndrome in Children with Limb DVT: A Bi-Institutional Cohort Study

Courtney A. Lyle, Elizabeth Gibson, Amy E. Lovejoy et al. · Thrombosis Research · 2012 · 24 citations

Thrombosis, Venous Thrombosis, Venous Disease Treatment +12